Tags: 340B, market access, hospital accounts, drug pricing, policy, Eli Lilly, Novo Nordisk, American Hospital Association, 340B Health, HRSA

Hospitals irate after Eli Lilly follows through on 340B ultimatum

By FieldPulse Editorial · June 23, 2026

Lilly's move to cut off 340B savings has turned a policy dispute into an immediate account-access problem for hospital-facing field teams.

Eli Lilly has moved from warning to enforcement in the 340B fight, and that makes this a field issue, not just a Washington policy story.

BioPharma Dive reported that Lilly cut off 340B savings last Thursday for hospitals that did not comply with its new claims-data requirements.

Hospital groups are now urging the Health Resources and Services Administration, or HRSA, to intervene, arguing that Lilly is acting outside the law and threatening patient access.

For hospital-facing Lilly reps, the practical implication is immediate.

Accounts that were receiving Lilly products at 340B discounts may now have to buy eligible drugs at wholesale prices instead.

The source cites a Government Accountability Office figure indicating that 340B pricing can mean discounts of roughly 20% to 50%.

When that kind of financial change lands, it changes the temperature of routine account conversations quickly.

Reps calling on affected systems should expect frustration, escalation to leadership, and tougher access questions this week.

Lilly's argument, as summarized by BioPharma Dive, is that the data submission requirement is meant to prevent duplicate discounts and diversion inside the 340B program.

The company told HRSA that the move was a necessary step after a small group of hospitals refused to comply voluntarily.

Hospital groups see it very differently.

340B Health and the American Hospital Association said Lilly is trying to rewrite the rules on its own, and both groups are pressing regulators to stop the policy.

The source also explains why this has broader commercial importance beyond Lilly.

A major hospital concern is that other manufacturers could adopt the same approach if regulators do not push back.

Novo Nordisk is already implementing its own data-sharing requirements, according to the article.

That means hospital account teams across pharma should treat this as a live precedent fight.

If Lilly's approach gains ground, manufacturers may push for more data before providing d.